# Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients

> **NCT07085117** · — · COMPLETED · sponsor: **Amgen** · enrollment: 5 (actual)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **DRUG:** Teprotumumab

## Key facts

- **NCT ID:** NCT07085117
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-02
- **Primary completion:** 2025-08-10
- **Final completion:** 2025-08-10
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07085117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07085117, "Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07085117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*